Myriad Genetics Fiscal First-Quarter 2017 Earnings Call

11/01/2016

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

Forward Looking Statements

Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements.

For additional information on GAAP to non-GAAP reconciliation see:
https://www.myriad.com/investors/gaap-to-non-gaap-reconciliation/

Non-GAAP Financial Measures

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. The Company's financial measures under GAAP include substantial one-time charges related to its acquisitions and ongoing amortization expense related to acquired intangible assets that will be recognized over the useful lives of the assets and charges related to executive severance. Management believes that presentation of operating results that excludes these items provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. A reconciliation of the GAAP to non-GAAP financial guidance is provided below.

	Fiscal Year 2017
GAAP diluted earnings per share	$0.34 - $0.44
Acquisition – amortization of intangible assets	$0.48
Acquisition – one time charges	$0.18
Non-GAAP diluted earnings per share	**$1.00 - $1.10**

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

First Quarter Fiscal Year 2017 Financial Results

	1Q17 Actual Results	1Q17 Actual Results (Excluding Assurex)	Guidance
Revenue	$177.5M	$170.3	$168 - $170 million
Adjusted EPS	$0.23	$0.25	$0.25 - $0.27
GAAP EPS	($0.02)	$0.00*	$0.14 - $0.16

* Based on higher than anticipated closing costs in the quarter due to the earlier than expected closing of the Assurex acquisition

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

Key Accomplishments in 1Q17

Area	Accomplishment
Market Expansion and Leadership in Hereditary Cancer	• Normalized trends by end of quarter • Signed physician networks agreements representing 70% of community oncology • 65% of revenue under long term contract; in network with 95% of plans
Diversifying the Product Portfolio	• Completed Assurex Health acquisition early; volume and revenue exceed expectations • GeneSight, Prolaris, and EndoPredict grew >50% on a volume basis • Non-hereditary cancer revenue reached 27% of total revenue in the 1Q17 compared to 7% three years ago • NOVA study first prospective validation of myChoice HRD • SOLO2 study provides further validation for BRACAnalysis CDx • First myChoice HRD Plus agreement with AstraZeneca
Increase International Contribution	• International revenue reached 5% of total sales compared to <1% three years ago • EndoPredict revenue grew 113% year-over-year with key reimbursement wins in France and Germany

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

Fiscal First-Quarter 2017 Revenue By Product

(in millions)

Product	1Q17	1Q16	YoY Growth
Hereditary Cancer	$139.3	$156.7	(11%)
Vectra DA	$11.6	$11.4	2%
Prolaris	$2.9	$0.7	314%
GeneSight	$7.2*	$0.0	NM
EndoPredict	$1.7	$0.8	113%
Other	$2.4	$2.3	4%
Total Molecular Diagnostic Revenue	**$165.1**	**$171.9**	**(4%)**
Pharmaceutical & Clinical Services	$12.4	$11.6	7%
Total Revenue	**$177.5**	**$183.5**	**(3%)**

* Represents revenue for the month of September only

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

Fiscal First-Quarter Financial Results

(in millions except per share data)	1Q17	1Q16	YoY Growth
Total Revenue	**$177.5**	**$183.5**	**(3%)**
Gross Profit	$137.5	$147.0	(7%)
Gross Margin	77.5%	80.1%	NA
Operating Income	$6.2	$43.3	(82%)
Adjusted Operating Income	$21.6	$46.5	(54%)
Adjusted Operating Margin	12.2%	25.3%	NA
Net Income	($1.2)	$30.3	NM
Diluted EPS	($0.02)	$0.42	NM
Adjusted EPS	**$0.23**	**$0.41**	**(44%)**

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

2Q17 and FY17 Financial Guidance

Metric	Fiscal Second-Quarter 2017	Fiscal Year 2017
Revenue	$188 to $190 million	$740 to $760 million
Diluted EPS	$0.06 to $0.08	$0.34 to $0.44
Adjusted EPS	$0.23 to $0.25	$1.00 to $1.10

For additional information on GAAP to non-GAAP reconciliation see: https://www.myriad.com/investors/gaap-to-non-gaap-reconciliation/

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

Review of Guidance Assumptions for FY17

Potential Downsides

1) Hereditary cancer out of network decisions

Base Case

1) Hereditary cancer decrease consistent with Q4 FY16 YoY decline
2) No incremental payer coverage for Vectra DA, GeneSight, Prolaris or EndoPredict
3) No revenue from myPath, myPlan Lung Cancer or myChoice HRD
4) No U.S. EndoPredict revenue
5) FY17 pharma & clinical services revenue < FY16
6) Ten months of Assurex Health revenue

Potential Upsides

1) Hereditary cancer oncology share stabilizes
2) New hereditary cancer indications provide growth
3) Additional private payer or Medicare coverage for Vectra DA, Prolaris or GeneSight
4) Preventive Care indication for GeneSight
5) UK, Canadian or German reimbursement for EndoPredict
6) Revenue from myPath Melanoma, myPlan Lung Cancer or myChoice HRD

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

Portfolio of Tests That Drive Cost Savings For Payers

	Value Proposition
MYRIAD myRisk® Hereditary Cancer	• Allows identification of patients with high predisposition to cancer where relatively inexpensive preventive measures can be taken to lower risk and reduce future healthcare costs
genesight®	• Shown to lower prescription drug costs and healthcare utilization with year one cost savings of ≈$2,600
Vectra DA disease activity test	• Demonstrated the ability in clinical studies to determine which patients are good candidates for biologic & non-biologic therapy and which patients are good candidates for tapering – shown to reduce biologic spend by 8% to 30%
Prolaris®	• Demonstrated cost savings of ≈$2,850 per patient tested
MYRIAD myChoice® HRD	• Can identify a subset of patients that have a increased response to PARP inhibitors – prevents broad drug utilization on patients who receive minimal benefit
EndoPredict®	• Can identify 60% of breast cancer patients who are at low risk and have less than a five percent risk of 10-year distant metastases and can safely avoid unecessary chemotherapy
MYRIAD myPath® Melanoma	• Demonstrated cost savings of ≈$1,500 per patient tested
MYRIAD myPlan™ Lung Cancer	• Can effectively allocate more or less aggressive therapy to patients based upon a molecular signature that determines patients at the highest or lowest risk of lung cancer specific mortality

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

Changing the Narrative on Our Four Most Important New Tests

$300M in incremental revenue if fully reimbursed

genesight®

- 1,200 patient clinical utility study near completion
- Payer demonstration projects

VectraDA® disease activity test

- Prospective clinical utility study currently enrolling
- Three demonstration projects with major payers on reducing biologic utilization

EndoPredict®

- Predictive study complete
- Multiple clinical utility and health economic studies underway

Prolaris®

- Additional 1,000 patient study showing ability to predict response to treatment
- Value-based contracting discussions
- Strong suite of existing utility data

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

myriad WHEN DECISIONS MATTER

Key Studies at American College of Rheumatology Meeting

Study	Using Vectra DA Score to Predict Flare and Sustained Remission (Hirata et al.)	Vectra DA Score and Prediction of Radiographic Progression (Brahe et al.)	Correlation Between Vectra Score and Myocardial Infarction and Infection (Curtis et al.)
Conclusion	"Patients with a Vectra DA score below 25 had a 14% risk of flare compared to 60% for patients with a high Vectra DA score; Patients with a Vectra DA score below 25 had a 64% rate of sustained remission compared to 0% in patients with a high Vectra DA score	"Patients with a Vectra DA score <44 had a 3% rate of radiographic progression compared to 31% in patients with a Vectra DA score >44; Vectra DA added significant predictive power to DAS28-CRP where DAS28-CRP added no predictive power to Vectra DA"	"Patients with a high Vectra DA score had almost twice the risk of myocardial infarction and five times the rate of serious infections when compared to patients with a low Vectra DA score"
Data	42 patients; p=0.03 (flare) p=0.006 (sustained remission)	180 patients; p=0.01	>16,000 patients

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

myriad WHEN DECISIONS MATTER

myChoice HRD Discriminating Power More Important in Future Studies



Mkt. Size (in bil.)	35,000	50,000	500,000	450,000	100,000	100,000

myChoice HRD positive patients myChoice HRD negative patients

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

myriad WHEN DECISIONS MATTER

10 Pivotal Clinical Study Results in Next 18 Months

Indication	Number of Studies	First Data Expected	Total Patients
HER2- metastatic breast cancer	4	Mar. 2017	160,000
Neoadjuvant TNBC	2	Mar. 2017	70,000
Other ovarian	3	Mar. 2017	50,000
Pancreatic	1	Dec. 2017	100,000
		Total	**360,000**

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

myriad WHEN DECISIONS MATTER

Launched Customizable Expanded myRisk Panel

1. Updating gene content to provide better care



2. Offering customizable format for customers



Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

Myriad Now Preferred Provider With Largest Oncology Physician Networks

70% of U.S. Community Oncology Practices

myriad® WHEN DECISIONS MATTER

Preferred Provider

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

Market Expansion Opportunity in Hereditary Cancer Exceeds $1B Annually

Indication	Added Market Potential	Guidelines	Contracting
Colon Cancer @ 5% Mutation Risk	+$100M	✓	55%
All Endometrial Cancer	+$150M	✓	55%
Breast Cancer <60 years	+$150M	FY17	FY18
All Pancreatic Cancer	+$125M	Partial	FY18
Prostate Cancer	+$120M	Partial	FY17
Colon Cancer Asymptomatic Market	+ $18B (6M patients)	✓	55%

4,400 patient breast cancer study nearing completion

Recent NEJM study shows 12% mutation rate in advanced prostate cancer

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

EndoPredict Grows 113% YoY; Reimbursement Expanding



- French public health care system funding beginning in 1H CY16 covering all patients
- German national reimbursement (GBA) covering in country testing in authorized major centers
- Submitting to U.K. NICE and Health Canada by end of CY16
- U.S. Launch in 2H FY17

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

Third Clinical Validation Presented at ASDP; Dossier Ready for Submission Upon Publication

myPath Melanoma Diagnostic Accuracy



myPath Melanoma Clinical Utility



Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.

Delivering on >$25 Billion Pipeline Opportunity



* Currently marketed

Oncology | Preventive Care | Urology | Autoimmune | Dermatology | Neuroscience

Copyright © 2017 Myriad Genetics, Inc., all rights reserved. www.Myriad.com.